Member Info for Energyshares

Rambo

Thanks I forgot Dr Tap ran the Lartruvo trial.

Lilly connection getting very interesting…

They state next step ongoing pre clinical that was in Nov 21

On pipeline they state discovery but Not disclosed.

Must be close to CTA and another milestone payment.

https://www.sec.gov/Archives/edgar/data/1811764/000181176421000017/pointbiopharmainvestorpr.htm

Agree BV but Point have had the licence for 3 years and Lilly 6 Months,Point stated they were waiting on Avacta results and have had a more insight into trial than anyone.

We should have had a CTA filing by now.

Three and half years ago

Avacta granted their first licence to the Pre/Cision technology to Point Bio.

The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.

That licence agreement now belongs to Eli Lilly.

Why after six months of owning this licence have they not submitted a CTA filing.

Are they keeping it under wraps while in talks.

They only have a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.

They only have one exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug.

So are they in talks for an exclusive licence for the broader pipeline to knock out the competition especially Novartis, or even a full T/O.

My one and only green box back on the scene other posters mentioned he had a bereavement can’t be a.rsed unblocking him to read, doesn’t Tombstone teeth give any of these trolls compassionate leave.

They would be better off collecting trolleys than being a troll.

Yes Timster it Works……..

This indicates that tumors are exposed over a prolonged period of time to doxorubicin.

And what is also interesting is that even the patients with medium FAP activity show a similar pattern.

Page 67 of 148

https://avacta.com/wp-content/uploads/2024/05/ARA-2024.pdf

To all the SH’s saying AS did a good job he did on his share holders.

Pair of Twats 9,069,810 share options between the since 2016.

Tony Gardiner CFO was paid a bonus of 36%. £154,000 on top of his salary of £238,000 what did he do for this bonus,

failed to see cash flow running low and pushed a car crash raise which crashed the shares by 66%

Use your votes get rid of this scum bag.

Village idiot still banging on about Novartis

FFS he has been trolling the board for 2 years

Up for re-election:

Let’s send him packing with AS pair of chuckle brothers….

6. To re-appoint Tony Gardiner as a Director of the Company in accordance with article 35 of the Articles who offers himself for re-appointment as a

Director of the Company.

Touk

Avacta haven’t got the funds to Ava6000 all the way and they have said they will partner to take to market

For Avacta to move AVA6000 into phase 2 they need a BP to partner in case of early AA approval they need to have manufacturing plans and postmarketing surveillance in place.

The entire process can take years and cost millions in order to approve new drugs that are safe as well as effective.

This is why I think a T/O will happen before P2.

If AVA6000 is the Holy Grail and safety & efficacy is nailed on the buyer would want to implement a platform P2 Trial so as many FAP tumour indications could be trialed at same time.

Platform trials are new but with deep pockets BP could get AVA6000 into as many cancer indications as possible ASAP.

The implementation of a platform trial assumes a high potential for recruitment in order to make the initial investment in the infrastructure more profitable. This is useful within the scope of pathologies where there are a lot of drug candidates, whether this involves innovative treatments, repositioning, optimization, or the combination of marketed treatments, or where the standard of care is rapidly changing.

A platform trial is a clinical trial in which multiple treatments or diseases are evaluated within the same protocol. A basket trial is when one therapy is tested on more than one disease or subtype of disease, and an umbrella trial is where multiple therapies are tested for a single disease with one or more subtypes.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756081/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220876/

Hope he is right…

In recent days, I have come around to the view (for numerous reasons) that something very significant could be going on behind the scenes at #AVCT.

A major commercial partnership, or else an outright takeover. I'm leaning towards the latter.

Most who have done an ounce of research on the company would agree that the equity should be valued 7-10x higher, as things stand.

The company sits on a globally unique technology in targeted oncology. Multiple board members have stated that "everyone wants it", that it's the Holy Grail of cancer treatment.

A host of misfortunates have stacked up to create an air of despair around Avacta, when really investors should be in jubilation. It will be almost impossible to come across another opportunity that Avacta now offers, in which (seemingly!) early stage clinical candidates are not only nearly-guaranteed to make it through to successful commercialization, but are moreover set to become blockbuster drugs. And the Company's technology could ultimately churn out many dozens of highly valuable oncology drugs.

This is my own view of what Avacta offers right now. I believe that it's an absolute given that the pre | CISION platform will be valued at tens of billions of dollars at some point in the future - almost certainly, when it's owned by a major pharmaceutical company, and said value is reflected in the owner's enlarged market cap.

The key task for Avacta's mgmt is in extracting the best value for existing holders. And a core component of that is in keeping a lid on the share count, at all costs.

Samsung Venture Investment Corporation,

Shinhan Venture Investment,

Smilegate Investment,

Shinhan Investment

Corporation,

Kolon Investment,

Stonebridge Ventures,

Gyeongnam Venture Investment.

All these funds have Billions invested in start up and emerging technology.

They all invested in Affyxell and will have done their DD on Avacta.

I wouldn’t be surprised if one of these funds takes a stake in Avacta and Pre/Cision.

Samsung Venture Investment Corporation is headquartered in Seoul and has a strong presence in the world's innovation hubs across the United States, Europe, Israel, India, China, and Japan. SVIC backs emerging technology startup founders, whom we believe will pioneer and shape the future.

Their fund is worth 3.5 billion KRW about £2 billion pounds.

“ And I've been reliably informed that it is simply premature, ”

Who is your source Eggy or Winbag

FFS this board

Great post JT

If Avacta see a CR 100% they receive AA soon.

Have they seen a CR ?

79% reduction last update Jan 24 if they have seen a CR they could be in the process of submitting a NDA for AA.

Complete Response

CR is defined as no detectable evidence of tumor. CR is generally measured through imaging studies (e.g., CT scans) or through histopathologic assessment (e.g., bone marrow biopsy or breast cancer resection specimens). Treatment effect measured by CR can be a surrogate endpoint to support accelerated approval, a surrogate endpoint to support traditional approval, or it can represent direct clinical benefit based on the specific disease, context of use, magnitude of the effect duration, disease setting, location of disease, available therapy, and the risk-benefit relationship. For hematologic malignancies such as acute leukemia, CR has been used as a clinical endpoint to support accelerated approval.

https://www.fda.gov/media/71195/download

Sherly Mosessian

Chief Scientific Officer SOFIE

Congratulations to my colleagues at Avacta on great progress with AVA6000. We are excited to bring value through [18F]FAPI-74 serving as a complementary diagnostic supporting therapeutic studies that target FAP.

Our regular idiots take some stick on twitter

Touk’s comment ……….Yeah right. Novartis are so short of cash they need to issue paper to fund a deal. FUD pure and simple.

LSE 🤡🤡🤡🤡🤡’s

Hi Rambo

I just posted top 7 BP in world Novartis number 8 many many more will be watching 👍

Who is watching Avacta ?

Fact:

Ely Lilly through their acquisition of Point now have eyes on Pre/Cision through their licence agreement.

Fact:

Sofie Biosciences with news from yesterday’s RNS they have access to the trial and will be seeing results first hand.

Fact :

GE Healthcare they have a licence agreement with Sofie for the rights outside-U.S. for [18F]FAPI-74

Fact:

Novartis • Novartis has acquired global development and commercial rights to therapeutic applications for iTheranostics’ library of FAP-targeted drugs licensed from University of Heidelberg

SOFIE affiliate, iTheranostics, executes agreement for its promising library of Fibroblast Activation Protein (FAP) targeted theranostics

Details undisclosed but Novartis and GE Healthcare have access to [18F]FAPI-74

So both will be receiving feedback from trial.

Fact:

LG Chem & Daewoong both have licence agreements on therapeutic affirmers and with Avacta now moving forward with peptide pipeline incorporating affimers they will be watching.

So four large BP players with access to AVA600 trial and two smaller players with a business relationship with Avacta.

Who is going to make the first move ?

* Johnson & Johnson.

* Roche.

* Merck.

* Pfizer.

* AbbVie.

* Sanofi.

* AstraZeneca.

Must all be feeling a bit left out.

Grab your popcorn going to be a very interesting second half of 2024.

https://sofie.com/2023/10/11/sofie-and-ge-healthcare-enter-licensing-agreement-to-develop-fap-pet-radiotracers/

https://sofie.com/2021/03/30/sofie-affiliate-itheranostics-executes-agreement-for-its-promising-library-of-fibroblast-activation-protein-fap-targeted-theranostics/